ASCRS 2020: Clinical trial results of KP1-121 0.25% for dry eye treatment

Edward Holland, MD, director of Cornea Services at Cincinnati Eye Institute, speaks with Ophthalmology Times' David Hutton on the results of a clinical trial using KP1-121 0.25% (loteprednol etabonate) for dry eye treatment during the 2020 ASCRS virtual meeting.


See more ASCRS coverage here

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.